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Abstract A degranulation inhibiting protein could be isolated 
from human plasma ultrafiltrate by a three-step purification 
method including ion-exchange chromatography, gelfiltration 
and affinity-chromatography. The protein was identified as com-
plement factor D by means of sequence analysis. Its degranula-
tion inhibiting activity was determined with regard to its effect 
on the FNLPNTL-induced lactoferrin secretion of human poly-
morphonuclear leukocytes. Complement factor D caused a dose-
dependent decrease of the FNLPNTL-stimulated lactoferrin de-
granulation down to 34% of stimulated controls. 
Key words: Complement factor D; Adipsin; Renal failure; 
Neutrophil; Degranulation 
1. Introduction 
Patients undergoing haemodialysis as a consequence of renal 
failure often are susceptible to bacterial mfections. This effect 
can be related with a restriction of leukocyte-functions [I] as 
chemotaxis, oxidative burst, degranulation and glucose-uptake. 
These dysfunctions may be attributed to physical damage of the 
cells during dialysis or to inhibitory factors, which should be 
found in plasma of these patients. An unlimited biological 
source of these proteins is the plasma ultrafiltrate obtained 
during haemodialysis. This fluid has been shown to contain 
some granulocyte inhibiting proteins. One of them was already 
described by Hori et al. [2] and another has been recently found 
by Tschesche et al. [3]. In this article we report on a degranula-
tion inhibiting protein isolated from human plasma ultrafiltrate 
and identified as complement factor D of the alternative com-
plement pathway. 
Complement factor D, Identical to human Adipsin [4], is a 
serine protease responsible for cleaving complement factor B 
into the fragments Ba and Bb [5]. The latter factor forms in 
combination with C3b the C3/C5 convertase of the alternative 
complement pathway [6]. Factor D has a molecular weight of 
24 kDa. consists of one polypeptide chain and is inactivated by 
diisopropyl-fluorophosphate [7]. In human plasma it is found 
to occur as an active enzyme, not as a zymogen [5]. Serum of 
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AhbrevwtlOns BCA, bicinchonmic aCId; DPBS, Dulbecco's phosphate-
buffered saline; ELISA, enzyme lInked Immunosorbent assay; 
FNLPNTL, formyl-norieucyl-leucyl-phenylalanyl-norJeucyl-tyrosyl-
leucm; PBS, phosphate-buffered saline; PMNL, polymorphonuclear 
leukocytes; PTH, phenylthiohydantom; SDS-PAGE, polyacrylamide 
gel electrophoresis in the presence of sodIUm dodecyl sulfate. 
healthy donors contains factor D in low concentrations (1-2 
,ug/mi), whereas this level can be increased ten-fold in serum of 
dialysis-patients suffering from chronic renal failure [8]. These 
plasma samples show an increase in alternative pathway activ-
ity [9] and a decreased activity of complement-mediated im-
mune complex clearance [10]. Factor D can be isolated from 
various sources such as serum, peritoneal fluid and urine 
[6,11,12]. No influence of factor D on leukocyte functions has 
been described previously. 
2. Materials and methods 
2.1 Matenals 
Plasma ultrafiltrates were obtained from University Frelburg, De-
partment of Medicine, Dialysis Unit. An ultrafiltration cell was pur-
chased from Amlcon (Beverly, USA). CM Sephadex C50 and Sephacryl 
S-100 were supplied by Pharmacla (Uppsala, Sweden). Fresh blood was 
supplied by Prof. Kleesiek, Herzzentrum Bad Oeynhausen (Bad Oeyn-
hausen, Germany) Ultravist 370 was a donation from Schering (Berlin, 
Germany). Methocel, Histopaque 1077 and anti-human lactofernn 
were obtamed from SIgma (Mtinchen. Germany). Culture dishes and 
immunoplates were purchased from Nunc (Roskilde, Denmark). BCA 
protem assay kIt was supplied by Pierce (Illinois, USA). 
].2 PurificatIOn of complement factor D from plasma ultraftltrates 
The followmg pUrIficatIOn steps were carried out at 4°C. Plasma 
ultrafiltrates of different patients were concentrated 500-fold using an 
Amlcon ultrafiltration cell wIth a YM3 membrane. The concentrated 
ultra filtrate was applied to a column (40 x 3 cm) ofCM Sephadex C50, 
prevIOusly eqUIlibrated with sodium phosphate buffer, pH 6.0 (0.05 M 
NaH,P04, 0.01 M EDTA. 0.2 M NaCl). The column was eluted wIth 
500 ml of a linear NaCI gradient (0.2-2.0 M) in the same buffer at a 
flow rate of60 ml/h. FractIOns belongmg to the same elution peak were 
pooled and concentrated. The sample contaming factor D was concen-
trated as described above. applied to a Sephacryl S-100-column (80 x 3 
cm) and eluted with Tns-buffer, pH 8.0 (0.02 M Tns, 0.005 M CaCl" 
o 5 M NaCl) at a constant flow rate of 12 mllh The fractions that 
corresponded to a molecular weIght of 14-30 kDa were pooled and 
concentrated One fraction showmg degranulatIOn mhlbltmg actIvIty 
was applied to a column (5 x 1.5 cm) of red Sepharose (prepared as 
deSCrIbed by Bbhme [13]), prevIOusly eqUlhbrated with 20 mM Tris. 
5 mM CaCI" pH 8.3, and eluted usmg 120 ml ora hnear NaCI gradient 
(0-1 M) m the same buffer (flow rate. 90 mllh). The fractions were 
pooled according to their elutIOn peaks, concentrated and analysed by 
electrophoresIs and PMNL degranulation tests. 
2.3. Electrophoresis 
To control the progress of purification, the different fractions were 
analysed by SDS-PAGE performed as deSCrIbed by Weber and Osborn 
[14] usmg 10.3% polyacrylamide gel. The silver staining of the gel was 
conducted according to Damerval [15]. 
2.4. Amino aCid sequencmg 
Automated Edman degradation for determination of the NH,-termi-
nal amino aCId sequence was performed on a mIcro sequencer (Model 
810. Knauer, Berlin) with on-hne PTH-analysis coupled to a Knauer 
HPLC-system eqUIpped with an Apphed BlOsystems PTH-CI8 column 
(220 x 2 I mm). 
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2.5 DettmmnatlOn of protein concentratIOn 
Protein concentrations were determined by means of a commercial 
BCA protein assay kit. 
2.6. Preparation of polymorphonuclear leukocytes 
Human PMNL were isolated from fresh blood of healthy donors by 
sedimentation of erythrocytes on a mixture of Ultravlst 370 (18.2 mil 
100 ml) and Methocel (1.4 g/100 ml H20) followed by centrifugation 
over Histopaque 1077 and hypotomc lysis of residual erythrocytes. The 
cells were suspended in DPBS-buffer (8 mM Na2HP04' 1.5 mM 
KH2P04, 140 mM NaCI, 2.7 mM KCI, 0.9 mM CaCI" 0.5 mM MgCI2, 
0.1 % glucose). 
2.7. P MNL degranulatIOn test 
DegranulatIOn was examined using 106 leukocytes m a final volume 
of 0.5 ml DPBS-buffer. Protein samples, preVIOusly dlalysed agamst 
PBS-buffer (DPBS-buffer without glucose), were preincubated at 37°C 
in culture-dishes (Nunc, Rosktlde. Denmark), then the prewarmed cells 
were added and the assay was incubated for 10 min at 37°C. Addition 
of 10-7 M FNLPNTL (Sigma), further mcubation at 37°C for 10 min 
and centrifugation of the supernatant followed. 
2.8. ELISA for lactoferrin 
The secretion of lactoferrin by PMNL was quantified using a specific 
sandwich-ELISA described by Schettler [16) and antibodies were pre-
pared according to Bergmann [17). 
3. Results and discussion 
3.1. Isolation oj Jactor D Jrom plasma ultra filtrate 
Complement factor D as a degranulation inhibiting protein 
was isolated from plasma ultrafiltrates by means of ion-ex-
change-chromatography, gel permeation chromatography and 
affinity-chromatography. Its homogeneity was shown by SDS/ 
PAGE (Fig. I) and its molecular weight was found to be ap-
proximately 24 kDa. 
3.2. Identification oj Jactor D 
The isoiated protein was identified as complement factor D 
by amino acid sequence determination. The first 30 amino acid 
residues of the protein were determined to be ILGGRE-
AEAHARPYMASVQLNGAHLCCGVL and found to be 
identical with the corresponding fragment of human comple-
ment factor D [18]. 
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Fig 1. Progress in purification of factor D from human haemodialysis 
ultrafiltrate SDS-PAGE, proteins visualised by silver stammg. Molecu-
lar weight marker (lane I), concentrated ultrafiltrate (lane 2). eluate 
from CM Sephadex C50 (lane 3). eluate from Sephacryl S-100 (lane 4), 
Isolated complement factor D (lane 6). 
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Fig. 2. Influence of complement factor D on FNLPNTL-stimulated 
lactoferrin degranulation of PMNL. Lactofernn release of cells not 
treated with factor D but stimulated with FNLPNTL was set to 100%. 
The data shown represent the results of five separate studies. 
3.3. Inhibition oj P MNL-degranulation by complement Jactor D 
The inhibitory activity of factor D on the granule secretion 
of human polymorphonuclear neutrophil leukocytes was exam-
ined with regard to its effect on PMNL stimulated with the 
synthetic peptide FNLPNTL. All experiments were conducted 
in a phosphate buffered saline medium containing 0.1 % glucose 
at a temperature of 37°C. The PMNL were pretreated with 
complement factor D for 10 min and stimulated with 
FNLPNTL (10-7 M) for a further 10 min. The lactoferrin secre-
tion of cells treated only with the formyl peptide was set to 
100%. Spontaneous degranulation of untreated cells tested 
under the same conditions was found to be 45% of this value. 
Pretreatment with factor D caused an inhibition of degranula-
tion dependent on its concentration. Fig. 2 shows the corre-
sponding dose-response curve. Preincubation with factor D in 
concentrations from 22.5 nM to 450 nM diminished the activat-
ing effect of 10-7 M FNLPNTL on the lactoferrin secretion of 
PMNL. Addition of factor D in concentrations from 135 nM 
to 450 nM decreased the extent of degranulation below the level 
of spontaneous degranulation. 
The concentration of complement factor D in serum of 
healthy human donors was found to be 40-80 nM [8]. In this 
range factor D lowered the FNLPNTL-induced lactoferrin-
degranulation of PMNL from 100% to 55%-65% in our exper-
iments. These results indicate. that complement factor D might 
regulate leukocyte enzyme release in healthy human blood as 
a counterpart of well known PMNL-stlmulating agents such as 
interleukin-8, tumour necrosis factor and leukotriene B4 . 
Patients suffering from end-stage renal failure can show a 
tenfold increase of factor D plasma-concentration up to 400-
800 nM [8]. This causes an increase in activity of the alternative 
complement pathway [9] but also a decrease in complement-
mediated immune complex clearance as described by Inagi [10]. 
Because of these pathophysiological effects, complement factor 
D has been identified as an important factor of dialysis-associ-
ated bioincompatibility [19]. Some membrane materials such as 
polyacrylonitril [20], polystyrol sulphonate [21] and polymeth-
ylmethacrylate [22) were found to adsorb factor D. Its removal 
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during haemodialysis might be beneficial for the immune sys-
tem of uraemic patients. 
In our experiments factor D applied in concentrations of 
200-450 nM caused a decrease ofFNLPNTL-induced lactofer-
rin-release down to 34%, while totally unstimulated cells 
showed a spontaneous lactoferrin-degranulation of 43%. This 
new physiological effect of complement factor D can contribute 
to a reduced host defence activity m patients with renal failure 
and high serum concentrations of factor D. 
Human complement factor D obviously has three different 
regulatory effects on the functions of the immune system. It acts 
(I) as an activator of the alternative complement pathway, (II) 
as an inhibitor of immune complex clearance and (III) as an 
inhibitor of premature leukocyte degranulation. The signal 
transduction pathway responsible for these effects will be an 
object of further studies. 
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